Electra Therapeutics is incandescent, glowing on the heels of a $183 million series C financing intended to fuel the biotech’s just-launched pivotal trial for its rare disease candidate. Nextech and ...
ELA026 demonstrated 100% overall response rate, improved survival, and a favorable safety profile in malignancy-associated HLH (mHLH), the most common type of sHLH with the poorest prognosis. Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results